Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
- DOI
- 10.1136/jitc-2024-009262
- Published
- 2024 Jul 24
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2024-009262,
title = {Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.},
author = {Yamamoto N and Kitano S and Koyama T and Ikeda M and Mizugaki H and Narikiyo T and Yamaguchi Y and Ishida T and Takubo R and Ogami C and Sekiya M and Nakagawa Y and Kuboki Y},
year = {2024},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2024-009262},
url = {https://doi.org/10.1136/jitc-2024-009262}
}RIS
TY - JOUR TI - Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers. AU - Yamamoto N AU - Kitano S AU - Koyama T AU - Ikeda M AU - Mizugaki H AU - Narikiyo T AU - Yamaguchi Y AU - Ishida T AU - Takubo R AU - Ogami C AU - Sekiya M AU - Nakagawa Y AU - Kuboki Y PY - 2024 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2024-009262 UR - https://doi.org/10.1136/jitc-2024-009262 ER -
APA
N, Y., S, K., T, K., M, I., H, M., T, N., Y, Y., T, I., R, T., C, O., M, S., Y, N., & Y, K. (2024). Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2024-009262
Source records
- pubmed · retrieved 2026-09-27T11:00:15.439Z